Scarica l'app Stockscreener
0.6706
9.74%
-0.0724
Precedente Chiudi:
$0.743
Aprire:
$0.721
Volume 24 ore:
252.83K
Relative Volume:
0.14
Capitalizzazione di mercato:
$2.27M
Reddito:
Utile/perdita netta:
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
1 W Prestazione:
-30.11%
1M Prestazione:
-63.75%
6M Prestazione:
-84.03%
1 anno Prestazione:
-92.34%
Intervallo 1D:
$0.00
$0.00
Intervallo di 1 settimana:
$0.6563
$1.0039
Portata 52W:
$0.6563
$9.17
Kairos Pharma, Ltd. Stock (KAPA) Company Profile
Nome
Kairos Pharma, Ltd.
Settore
Industria
Telefono
-
Indirizzo
-
Compare KAPA vs VRTX, MRNA, REGN, ARGX, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KAPA
Kairos Pharma, Ltd.
|
0.6706 | 2.27M | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
Kairos Pharma, Ltd. Borsa (KAPA) Ultime notizie
Kairos Pharma reports positive interim data for prostate cancer trial By Investing.com - Investing.com Nigeria
Why Is Kairos Pharma Stock Falling Today?Kairos Pharma (AMEX:KAPA) - Benzinga
Kairos Pharma reports positive interim data for prostate cancer trial - Investing.com
What's Moving Biotech Stocks Pre-Market? Bluejay Diagnostics (NASDAQ:BJDX), Kairos Pharma (NYSE:KAPA), Rezolute (NASDAQ:RZLT) in Focus - kalkine.ca
Kairos Pharma reports positive interim data for prostate cancer trial By Investing.com - Investing.com Canada
Kairos Pharma reports positive Phase 2 interim PFS data; median PFS 17.7 vs 2 months - TradingView
Kairos Pharma, Ltd. (KAPA) Stock Price & News - Syfe
Kairos Pharma to Present and Moderate at Discovery on Target Conference in Boston, MA - Yahoo Finance
Kairos (KAPA) Soars +3.47% Past $1.88 — New Highs Ahead? 2026-09-22Call Flow Alert - dars.gov.et
Kairos Pharma (AMEX: KAPA) Releases Investor Presentation on September 14 at H.C. Wainwright Conference - Kalkine Media
Kairos Pharma at H.C. Wainwright conference: resistance strategy in focus By Investing.com - Investing.com UK
Kairos Pharma (KAPA) to present clinical update at H.C. Wainwright investor conference - stocktitan.net
Kairos Pharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference - Yahoo Finance
Kairos Pharma Announces 1-for-7 Reverse Stock Split to Meet NYSE American Listing Rules - Minichart
Kairos Pharma Announces 1-for-7 Reverse Stock Split - Yahoo Finance
Kairos Pharma to conduct 1-for-7 reverse stock split By Investing.com - Investing.com Canada
Kairos Pharma to Conduct 1-for-7 Reverse Stock Split - Yahoo Finance
Kairos Pharma to conduct 1-for-7 reverse stock split - Investing.com
Kairos (KAPA) Results Breakdown: EPS Falls Short of Its Estimate under the Current Snapshot; Latest Reaction: Shares Move 1.52% Lower on the DayEarnings Surprise Stocks - careplusvn.com
Kairos (KAPA) Results Check: Reported EPS Misses Expectations in the Reported Period; Price Reaction: The Stock Ends Down 4.68% in Latest TradingFiscal Year Earnings - careplusvn.com
Kairos Pharma (KAPA) Slips 1.07% to $0.35 as Biotech Consolidation Keeps $0.33 Support in FocusStock Analysis - careplusvn.com
KAPA Q1 2026 Earnings: EPS Misses Estimates Amid Pre-Clinical Stage OperationsSaaS Earnings Trends - careplusvn.com
KAPA Q1 2026 Earnings: Narrow Loss Slightly Misses Estimates; Shares Climb 3.71%Earnings Whisper Number - careplusvn.com
Kairos Pharma (KAPA) Tests Support as Stock Slides to $0.29Volume Nodes - careplusvn.com
Kairos Pharma partners with Bayer on prostate cancer study - Investing.com
Kairos Pharma Announces Strategic Collaboration with Bayer to Enhance XOFIGO Activity in Metastatic Prostate Cancer - Yahoo Finance
Kairos Pharma Sees Significant Decline as Stock Approaches Key Support LevelCounter Trend Trade - careplusvn.com
Kairos Pharma Sees Significant Decline as Stock Approaches Key Support LevelProtective Put - dars.gov.et
Kairos Pharma Ltd. (KAPA) Drops 8.8%, Approaches Key Support LevelBear Flag - careplusvn.com
Kairos Pharma (KAPA) Stock Surges Over 22% After Hours: Why is it Moving? - Benzinga
CEO.CA's Inside the Boardroom: Kairos Pharma Might Change Cancer Treatment Forever - tradingview.com
KAPA Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Continues DevelopmentFiscal Year Earnings - careplusvn.com
All You Need to Know About Kairos Pharma, Ltd. (KAPA) Rating Upgrade to Buy - Yahoo Finance
Should I buy Kairos Pharma, Ltd. (KAPA) - Zacks Investment Research
Kairos Pharma Recaps Important Acquisitions and Details Plans for the Balance of 2026 in Letter to Shareholders - Lelezard
KAPA - Finviz
Kairos Pharma | DEF 14A: Definitive information statements - Moomoo
Kairos Pharma, Ltd. to Present at the LD Micro Invitational XVI - TMX Newsfile
Kairos Pharma, LTD. 1Q 2026: Revenue $0 Net loss $(1.65M) — 10-Q Summary - tradingview.com
Kairos Pharma, Ltd. Sets Annual Meeting of Shareholder Date and Provides Update on Its Annual Filings - Yahoo Finance
Kairos Pharma Investor News: Rosen Law Firm Encourages Kairos Pharma, Ltd. Investors to Inquire About Securities Class Action Investigation – KAPA - Business Wire
Rosen Law Firm Encourages Kairos Pharma, Ltd. Investors to Inquire About Securities Class Action Investigation – KAPA - Business Wire
Kairos Pharma signs deal for Celyn Therapeutics’ CL-273 - Pharmaceutical Technology
Kairos Pharma acquires lung cancer drug assets from Celyn Therapeutics - Mugglehead Investment Magazine
Kairos Pharma (KAPA) Institutional Ownership 2026 - MarketBeat
Kairos Pharma Wins R&D Award for Innovative Advanced Prostate Cancer Trial with ENV 105 - Clinical Trials Arena
What is the current Price Target and Forecast for Kairos Pharma, Ltd. (KAPA) - Zacks Investment Research
Kairos Pharma, Ltd. (KAPA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Kairos Pharma, Ltd. (KAPA) stock price, news, quote and history - Yahoo Finance UK
Kairos Pharma, Ltd. Azioni (KAPA) Dati Finanziari
Non sono disponibili dati finanziari per Kairos Pharma, Ltd. (KAPA). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
1.35%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):